<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82188">
  <stage>Registered</stage>
  <submitdate>2/08/2007</submitdate>
  <approvaldate>7/08/2007</approvaldate>
  <actrnumber>ACTRN12607000406404</actrnumber>
  <trial_identification>
    <studytitle>Does dexamethasone influence blood cortisol levels after laparoscopic cholecystectomy?</studytitle>
    <scientifictitle>Dexamethasone administration for postoperative nausea and vomiting in laparoscopic cholecystectomy and perioperative cortisol levels.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Laparoscopic cholecystectomy</healthcondition>
    <healthcondition>Gallstone disease</healthcondition>
    <healthcondition>Cholecystitis</healthcondition>
    <healthcondition>Postoperative nausea and vomiting</healthcondition>
    <healthcondition>Postoperative pain</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Dexamethasone 8mg once only intravenously at commencement of anaesthesia for laparoscopic cholecystectomy.  All participants (both active and control groups) receive tropisetron 2mg intravenously at the completion of surgery. Dexamethasone and tropisetron are used to prevent postoperative nausea and vomiting.</interventions>
    <comparator>The placebo is 2ml of normal saline given once only at induction of anaesthesia.  </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Perioperative cortisol levels </outcome>
      <timepoint>Measured immediately preoperatively, 20 minutes after administration of dexamethasone and 8 hours postoperatively.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pain scores using visual analgogue scale (VAS) or numeric rating scale (NRS).</outcome>
      <timepoint>These endpoints will be measured twice daily on the operative day and for 2 days postoperatively.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Episodes of nausea</outcome>
      <timepoint>These endpoints will be measured twice daily on the operative day and for 2 days postoperatively.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Episodes of vomiting</outcome>
      <timepoint>These endpoints will be measured twice daily on the operative day and for 2 days postoperatively.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Analgesia and antiemetic use</outcome>
      <timepoint>These endpoints will be measured twice daily on the operative day and for 2 days postoperatively.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients undergoing laparoscopic cholecystectomy with none of the exclusion criteria.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Non English speakingInsulin requiring diabetesPatients receiving exogenous steroid treatment for other illness.Unable to receive standardised inhalational anaesthesia.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed envelopes opened at the time of randomisation</concealment>
    <sequence>Computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>The subjects, clinician administering the drug and the assessors will be blinded.</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/09/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St Vincents Health Melbourne</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Department of Anaesthesia
St Vincents Health</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>No secondary sponsor</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary endpoint of the study is to determine if dexamethasone 8mg, administered at the start of an anaesthetic to prevent postoperative nausea and vomiting, reduces the level of cortisol postoperatively.  Cortisol is a hormone produced by the adrenal glands in times of stress (such as at operation).  Dexamethasone is frequently used to prevent nausea and vomiting after operations and is known to reduce cortisol levels in patients not having operations.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincents Health Melbourne</ethicname>
      <ethicaddress>Melbourne VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Kara Allen</name>
      <address>Department of Anaesthesia
St Vincent's Hospital
PO Box 2900
Melbourne
Fitzroy VIC 3065</address>
      <phone>+61 3 92884253</phone>
      <fax />
      <email>kara.allen@svhm.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Kara Allen</name>
      <address>Department of Anaesthesia
St Vincent's Hospital
PO Box 2900
Melbourne
Fitzroy VIC 3065</address>
      <phone>+61 3 92884253</phone>
      <fax />
      <email>kara.allen@svhm.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>